QDIS Blog

A blog about chemistry, drug development, science, and technology

Pages (999999): [1] 2 3 » ... Last »

October 12, 2006

New Drug Effective Against Bird Flu

by @ 8:18 am.  Filed under Science

Drug researcher reports that a new peptide fragment shows activity against influenza A including the H5N1 avian flu in vitro. The fragment is only 20 amino acid residues

New drug provides effective defence against bird flu

The above headline is misleading since the work has only been done in vitro and not in patients. I don’t have access to the actual article so I can’t comment on the amino acid sequence.

The peptide seems to prevent viruses from entering the cell and the survival rate for the animal models was 100%. While this is promising, there have been many cases of drugs showing excellent activity in animal models but never working in humans. It will be interesting to see if this develops and goes beyond the preclinical stage. Since this work comes from the University of Wisconsin-Madison, it would take a deal with a pharmaceutical or biotech company before it moves to the next stage.

Sources

Abstract: INHIBITION OF INFLUENZA VIRUS INFECTION BY A NOVEL ANTIVIRAL PEPTIDE THAT TARGETS VIRAL ATTACHMENT TO CELLS — Jones et al., — The Journal of Virology

Technorati Tags: , , ,

Email Ed Vawter



Related Posts:
  • Sanofi Bird Flu Vaccine Nod From FDA Panel Even Though It Is Only Modestly Effective
  • Initial Tests Show China’s Bird Flu Vaccine Safe
  • Microchip to Detect Bird flu
  • New Information on Bird Flu in Humans
  • FDA panel to vote on America’s first bird flu vaccine

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    The FDA and Nanotechnology

    by @ 8:18 am.  Filed under Science, FDA

    One of the topics that the FDA will need to deal with is the whole topic of nanotechnology. It has been a hot topic recently due to an public meeting on this topic recently (Oct. 10, 2006).

    United Press International - Health Business - Analysis: FDA comes up short on nanotech:

    The above UPI report was released before the FDA meeting mentioned above. This paragraph caught my attention.

    Taylor noted that the FDA’s budget would have to be increased by 50 percent to bring it up to its 1996 level. And the agency’s budget for next year won’t improve without action by Congress. President Bush’s 2007 proposed budget will increase the gap between responsibilities and capacity to 56 percent.

    Given how important the FDA is (they oversee 25% of the gross national product) and how much work they have to do an increasing budget gap is cause for alarm. Especially in light of the recent rash of problems with spinach and lettuce which seems to indicate that there may not be enough oversight in this area. Add to this trying to keep up with the rapid advances in many areas particularly nanotechnology and you have a recipe for disaster.

    There are at least 320 products using nanotechnology already on the market although many of these fall outside the purview of the FDA and about 200 products that would fall under the FDA’s rules are under development.

    This is another example of science leading public policy when it comes to cutting edge technologies. I have some experience in this regard when I worked for a company developing polymer based drugs and educating the FDA on how the polymers were characterized. We had to educate some FDA folks as to what the analytical methods were we were using and how the technology worked and why we were using as well as other methods we tried that may not have worked and why they didn’t work.

    FDA told to watch nanotech products for risks - Yahoo! News

    The above story focuses on the fact that the FDA is ill equipped to deal with nantech products and the possible safety questions. The FDA has created an internal task force to look into nanotech and should have a report out in about nine months (mid-summer 2007). While I applaud them doing this, it seems to be quite late to the party. Nanotechnology has been popular for some time now and many products have been developed based on it. As quick search of Google news archive on nanotechnology shows articles back to March 1991.

    A quick search for nanotechnology in Google trends shows searches for it being fairly flat but the really interesting fact to note is that the US does not even appear in the top 10 cities searching for this term. india occupies 6 of the top ten cities

    Picture 1-8

    Looking at the trends by country is even more revealing.

    Picture 2-4

    Another interesting tidbit is that Iran is number two for searching for the term nanotechnology. The US is down at the number 8 position. I’m not sure what to make of this but it is interesting.

    Some other news stories:

    FDA gets mixed advice on nanotechnology
    Experts give FDA advice for regulating nanotechnology
    Nanotechnology: It’s Knocking on FDA’s Door

    Other Resources

    • FDA web page on Nanotechnology
    FDA nanotechnology - Yahoo! Search Results
    FDA nanotechnology - Google Search

    Yahoo! News Search Results for fda nanotechnology
    FDA nanotechnology - Google News

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • No related posts

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Genentech and CGI Pharmaceuticals Enter Into Agreement

    by @ 8:02 am.  Filed under Pharma News

    Although not a merger or acquisition, this recent deal between Genentech and CGI Pharmaceuticals is still part of the activity in deals and mergers recently.

    Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications: Financial News - Yahoo!
    Finance

    It is interesting that the deal seems to be broad in scoop covering discovery, development and manufacturing activities but more interesting is that the target has not been announced, only that it is in the area of oncology and autoimmune disorders. It is interesting not so much for what is says, but in the lack of details.

    It includes a $25 million upfront payment and could come to $500 million if defined milestones are met over the next few years (the time frame was not spelled out).

    Disclosure: I own a few shares of Genentech.

    Technorati Tags: , ,

    Email Ed Vawter



    Related Posts:
  • Organon and Pharmacopeia Enter Into Alliance
  • FTC asks for more info on Genentech, Tanox merger
  • GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
  • Biotech Startup May Rise Out of Icos Merger
  • Genentech and Seattle Genetics Announce Agreement for SGN-40

  • Bookmark it with: | del.icio.us del.icio.us | Digg It Digg it | Furl Furl | Simpy Simpy | Spurl Spurl | My! Yahoo My Yahoo! |

    Pages (999999): [1] 2 3 » ... Last »

    [powered by WordPress.]

    QDIS: blogging about chemistry, drug development, science and technology.

    Internal Links

    Categories

    Search This Blog

    Archives

    October 2006
    S M T W T F S
    « Sep   Nov »
    1234567
    891011121314
    15161718192021
    22232425262728
    293031  

    Search Entire Site

    Subscribe (It's Free!)

    Performancing

    Chemistry, science, and technology for the future.

    logo2

    General Links

    Blog Links

    Chemistry Journal Feeds

    Chemistry Feeds

    42 queries. 1.327 seconds